Voclosporin Shows Promise as Potential Treatment for Lupus Nephritis
Aurinia Pharmaceuticals’ product candidate voclosporin continues to show promise in patients with lupus nephritis (LN), according to the company. In addition to meeting complete and partial remission endpoints at 48 weeks of the trial, treatment with voclosporin also met secondary endpoints, such as reduction in speed of remission, disease…